Research programme: thymosin beta 4 sulfoxide derivatives - GrannusAlternative Names: GBL 101
Latest Information Update: 12 Sep 2015
At a glance
- Originator Grannus BioSciences
- Mechanism of Action Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Respiratory tract disorders
Most Recent Events
- 20 Feb 2007 Preclinical trials in Respiratory tract disorders in United Kingdom (unspecified route)